重组人脑利钠肽与左西孟旦联合治疗急性失代偿性心力衰竭的临床效果观察  

Observation on the clinical effect of recombinant human brain natriuretic peptide combined with Simendan in the treatment of acute decompensated heart failure

作　　者：徐艳慧[1] XU Yan-hui(Internal Medicine Cardiovascular Department,Chifeng Hospital,Chifeng 024000,China)

机构地区：[1]赤峰市医院心内科,024000

出　　处：《中国实用医药》2020年第33期79-81,共3页China Practical Medicine

摘　　要：目的观察重组人脑利钠肽与左西孟旦联合治疗急性失代偿性心力衰竭的临床效果。方法118例急性失代偿性心力衰竭患者,应用随机数字表法分为对照组和观察组,各59例。对照组应用重组人脑利钠肽治疗,观察组应用重组人脑利钠肽联合左西孟旦治疗。对比两组临床效果、不良反应发生情况及治疗前后心功能指标。结果观察组治疗总有效率为94.92%,对照组治疗总有效率为81.36%;观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)对比,差异无统计学意义(P>0.05);治疗后,两组LVEF均高于治疗前,且观察组LVEF(46.3±0.1)%高于对照组的(41.8±0.1)%,差异有统计学意义(P<0.05);治疗后,两组LVEDD与治疗前及组间对比,差异无统计学意义(P>0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。结论重组人脑利钠肽与左西孟旦联合治疗急性失代偿性心力衰竭的临床效果显著,是一种有效的治疗方案。Objective To observe the clinical effect of recombinant human brain natriuretic peptide combined with Simendan in the treatment of acute decompensated heart failure.Methods A total of 118 patients with acute decompensated heart failure were divided into control group and observation group according to random numerical table,with 59 cases in each group.The control group was treated with recombinant human brain natriuretic peptide,and the observation group was treated with recombinant human brain natriuretic peptide combined with Simendan.The clinical effect,occurrence of adverse reactions and cardiac function indexes before and after treatment were compared between the two groups.Results The total effective rate of treatment of the observation group was 94.92%,which was 81.36%of the control group;the total effective rate of treatment of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDd)between the two groups(P>0.05).After treatment,LVEF of the two groups was higher than that before treatment,and LVEF(46.3±0.1)% of the observation group was higher than(41.8±0.1)%of the control group,and the difference was statistically significant(P<0.05).After treatment,there was no statistically significant difference in LVEDD between the two groups and compared with those before treatment(P>0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of recombinant human brain natriuretic peptide and levosimendan has significant clinical effects in the treatment of acute decompensated heart failure,which is an effective treatment regimen.

关 键 词：重组人脑利钠肽 左西孟旦 急性失代偿性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]